Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2016

View Archived Issues

Alectos receives orphan drug designation for MK-8719

First-in-human results for nesvacumab in patients with advanced solid tumors

US Phytotherapy demonstrates dengue virus inhibition in preliminary cell culture studies

COMP as a novel prognostic biomarker in breast cancer

FDA grants orphan drug designation to DelMar's VAL-083

Roche patents beta-secretase 1 inhibitors

Lead Discovery Siena discloses guanidine derivatives

Merck & Co. reports TrK-A inhibitors

NITD-008 and galidesivir improve survival and reduce viremia in AG129 mouse model of ZIKV infection

BioMarin's BMN-250 begins phase I/II trial, awarded European orphan drug designation for MPS IIIB

Repatha becomes available in Japan

Positive interim data from phase II trial of KRN-23 as treatment of tumor-induced osteomalacia

AbbVie and CytomX collaborate on Probody drug conjugate targeting CD71

Galapagos reports 20-week phase II results for filgotinib in Crohn's disease

Sitagliptin is not beneficial in nonalcoholic fatty liver disease study

TapImmune begins phase II trial for cancer vaccine TPIV-200

AstraZeneca to transform drug discovery and development through new integrated genomics initiative

Deutetrabenazine exhibits positive effects on tics in adolescents with Tourette syndrome

Achaogen awarded contract option by NIAID to support LpxC inhibitor research

Opthea provides update on phase I trial for OPT-302

FDA gives orphan drug designation to cannabidiol for TSC

SFARI launches SPARK autism research study

Janssen files for Japanese approval of Simponi for the treatment of ulcerative colitis

FDA grants orphan drug designation to NK-012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...